HE ROLE OF FATTY ACID CONTENTS OF ERYTHROCYTES MEMBRANES IN CARDIOHEMODYNAMICS DISORDER IN GOUT PATIENTS WITH INSULIN RESISTANCE SYNDROME

Aim. To assess the specifics of fatty acidic contents of erythrocyte membranes, and morpho-functional disorder of the left ventricle (LV) in gout patients depending on the syndrome of insulin resistance (IR).

Material and methods. In the study, 117 males participated, age 39 to 55 y o., with gout. Among them, 43.6% presented with normal HOMA-IR, and the rest had IR. Fatty acid content of membrane lipids assessed, as the morphofunctional properties of theLV, with the types ofLV geometry and its diastolic function assessment, according to presence or absence of IR.

Results. Changes of fatty acid contents in IR and gout patients cells membranes are characterized by increased amount of saturated fatty acids and decreased — of unsaturated, and in the pool of unsaturated acids there is increase of monoenic, but significant decrease of polyenic acids. In the pool of polyunsaturted acids there is increased amount of y-linoleic and dihomo-y-linoleic and significant decrease of arachidonic and docosapentaenoic acids. It is found, that cardiohemodynamics parameters in gout patients do significantly differ with IR. In males with gout and IR the prevailing variant of theLV architectonics was concentric hypertrophy (49,3%; p<0,05). Patients with the normal parameters of glucose-insulin homeostasis more commonly showed normal geometry (26,6%; p<0,05) and eccentric hypetrophy ofLV (46,8%; p<0,05). Diastolic dysfunction of theLV was registered 2,8 times more frequently in the insulin resistant patients. There were correlations found of hyperuricaemia, increased insulin level and changes of fatty acidic content and cardiohemodynamics parameters.

Conclusion. The found relations of the fractional contents of fatty acids, morphofunctional disorder of theLV and parameters of carbohydrate metabolism might impact significantly the development of cardiovascular complications in this category of patients.

1. Loginova ТК, Shostak NA, Kopelev AA. Heart lessions in patients with gout. Klinitsist 2008; 3: 20-4. (In Russ.).

2. Filippatos GS, Ahmed MI, Gladden JD, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: рotential mechanistic insights from epidemiological data. Eur Heart J 2011; 32 (6): 712-20. DOI: 10.1093/eurheartj/ehq473.

3. Volkova AR, Krasil'nikova EI, Berkovich OA, et al. Obesity and other cardiovascular risk factors in patients with heart ischemic disease with coronarography confirmed atherosclerosis. Vestnik Rossiyskoy voenno-meditsinskoy akademii 2010; 4 (32): 59-62. (In Russ.)

4. Titov VN, Rozhkova TA, Amelyushkina VA. Fatty acids, triglycerides, hypertriglyceridemia, hyperglycemia and insulin. M.: Infra-M, 2016. p. 197. (In Russ.)

5. Kimball SR, Jefferson LS. Control of translation initiation through integration of signals generated by hormones, nutrients, and exercise. J Biol Chem 2010; 285 (38): 29027-32. DOI: 10.1074/jbc.R110.137208.

6. Abbasi F, Okeke Q, Reaven GM. Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR). Acta Diabetol 2014; 51(2): 193-7. DOI: 10.1007/s00592-013-0461-2.

7. Lang MR, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28 (1): 1-39. DOI: 10.1016/j.echo.2014.10.003.

8. Vasyuk YuA. Recommendations for the quantitative assessment of the structure and function of the heart chambers. Rus J of Cardiol 2012; 3 (95): 1-28. Suppl. 1 (In Russ.).

9. Chumakova GA, Veselovskaya NG, Gritsenko OV, et al. Epicardial Adiposity as Risk Factor of Coronary Atherosclerosis. Kardiologiia 2013; 53 (1): 51-5. (In Russ.)

10. Koshel'skaya OA, Sushkova AS, Zhuravleva OA, et al. Prediction of basal glycaemia dynamics during treatment with 6-month lipid-lowering therapy in patients at high risk of cardiovascular disease. Diabetes Mellitus 2017; 20 (5): 374-83. (In Russ.) DOI: 10.14341/DM8633.

11. Shul'kina SG, Smirnova EN. Diagnostic value of cystatin C and collagen type IV in patients with hypertension and obesity. Arterial Hypertension 2017; 23 (6): 552-60. (In Russ.) . DOI: 10.18705/1607-419X-2017-23-6-552-560.

12. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009; 11: 9. DOI: 101017/ S146239940900101X.

13. Golovach IYu. Left ventricular hypertrophy and arterial hypertension: new pathogenetic and therapeutic concepts. Consilium Medicum 2013; 10: 13-7. (In Russ.).

14. Sharonova L, Verbovoy A, Tsanava I. Adipokines and echocardiographic parameters in patients with type 2 diabetes mellitus, gout, and a combination thereof. Medicine in Kuzbass 2016; 15 (1): 33-41. (In Russ.)

15. Shukurova SM, Hamidov NH, Toyrov HK. Myocardial structure and function in patients with gout. Eurasian Journal of Internal Medicine 2016; 3: 33-6. (In Russ.)

16. Krishnan E, Hariri A, Dabbous O, et al. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 2012; 18 (3): 138-43. DOI: 10.1111/j.1751-7133.2011.00259.x.

17. Mule' G, Nardi E, Costanzo M, et al. Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men. Nutr Metab Cardiovasc Dis 2013; 23 (8): 715-22. DOI: 10.1016/j.numecd.2012.01.007.

18. Keenan T, Zhao W, Rasheed A, et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol 2016; 67 (4): 407-416. DOI: 10.1016/j.jacc.2015.10.086.

19. Kushnarenko NN, Govorin AV. Clinical importance of endothelial dysfunction and insulin resistance syndrome in patients with gout associated with arterial hypertension. Rational Pharmacotherapy in Cardiology 2013; 9 (5): 482-7. (In Russ.)

20. Aronow WS. Hypertension and left ventricular hypertrophy. Ann Transl Med 2017; 5 (15): 310. DOI: 10.21037/atm.2017.06.14.

21. Desai CS, Ning H, Lloyd-Jones DM. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart 2012; 98 (4): 330-4. DOI: 10.1136/heartjnl-2011-300819.

22. Markelova EI, Barskova VG, Volkov AV, et al. Risk factors of left ventricular hypertrophy in patients with gout. Rheumatology science and practice 2012; 5 (54): 45-50. (In Russ.)